Browse Category

NYSE:HMY News 9 December 2025 - 12 January 2026

Harmony Gold (HMY) stock rebounds in premarket as gold steadies after CME margin jolt

Harmony Gold (HMY) stock rebounds in premarket as gold steadies after CME margin jolt

Harmony Gold’s U.S. shares rose 3.4% to $20.63 in premarket trading Tuesday, recovering some ground after an 8.2% drop Monday. Gold prices rebounded 1.3% as traders awaited Federal Reserve meeting minutes, following a margin hike that triggered sharp losses in metals and mining stocks. Harmony’s ADR closed at $19.95 Monday after hitting $19.76 intraday. The stock has ranged from $8.08 to $22.25 in the past year.
Canada Stock Market Today: TSX Edges Higher as Gold and Banks Lead Rally Ahead of Fed and BoC Decisions – December 9, 2025

Canada Stock Market Today: TSX Edges Higher as Gold and Banks Lead Rally Ahead of Fed and BoC Decisions – December 9, 2025

Toronto’s stock market finished modestly higher on Tuesday, December 9, 2025, as investors leaned into Canada’s familiar power duo – resource producers and big banks – while positioning for back‑to‑back central‑bank decisions from the U.S. Federal Reserve and the Bank of Canada on Wednesday. TSX After the Bell: Modest Gain Near Record Territory Canada’s benchmark S&P/TSX Composite Index closed around 31,266, up roughly 0.3% on the day, recovering a portion of Monday’s pullback and keeping the index within striking distance of last week’s record high near 31,542 points. Investing.com+1 Intraday, the TSX traded just above 31,100, with buyers stepping in whenever prices drifted lower, a pattern consistent
9 December 2025

Stock Market Today

AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
Go toTop